By Sharon Reynolds
Clearity offers psychosocial support to caregivers through our Steps Through OC program. If you would like personal one-to-one assistance with the stress and challenges associated with caring for a loved one with an ovarian cancer diagnosis, our … Read more
Clearity’s Perspective: New research demonstrates how paclitaxel (Taxol), a commonly used and effective drug for OC, works by disrupting cancer cell division. This research helps us to get a better understanding of the mechanism through which paclitaxel (Taxol) destroys cancer … Read more
Michael Eselun, Clearity’s Oncology Chaplain, sat down with our Director of Education, Danielle Peterson, to discuss what occasions like the Jewish New Year Celebration, Rosh Hashanah, and Día de los Muertos can teach us about the role the contemplation of … Read more
A new liquid biopsy test developed by researchers at USC Norris Comprehensive Cancer Center has shown promise to distinguish which pelvic masses are benign and which are tumorous, a development that could aid early diagnosis of high-grade serous ovarian carcinoma … Read more
Oncologists treating ovarian cancer need to be proactive to prevent or reduce the likelihood of adverse effects associated with poly (ADP-ribose) polymerase (PARP) inhibitors, noted authors of a review in the ASCO Educational Book.
William Tew, MD, of Memorial Sloan … Read more
The FDA has approved the first blood test that can help identify hundreds of potentially cancer-associated hereditary variants. The Invitae Common Hereditary Cancers Panel evaluates a blood sample to identify DNA variants in 47 genes associated with an elevated risk … Read more
By Hayden E. Klein
For Ovarian Cancer Awareness Month in September, Rebecca Brooks, MD, talked to The American Journal of Managed Care® (AJMC®) about how genetics and family history play a large role in ovarian cancer … Read more
Key Points:
By Andrea S. Blevins Primeau, PhD, MBA
Adding hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery improves long-term outcomes in patients with stage III epithelial ovarian cancer, according to updated trial results published in The Lancet Oncology.
These 10-year … Read more
By Andrea S. Blevins Primeau, PhD, MBA
A Ludwig Cancer Research study has shown that combining adoptive T cell therapy (ACT) with an innovative, personalized cancer vaccine under development at the Lausanne Branch of the Ludwig Institute for Cancer Research … Read more
Clearity offers psychosocial support through our Steps Through OC program for patients, survivors and caregivers. If you would like personal one-to-one assistance with the stress and challenges associated with an ovarian cancer diagnosis, our team of OC Counselors can help … Read more
Shared by Norma Rabago
When Juana Padron, a 40-year-old mother of four, chose to have a genetic test, going against her friends and family’s advice was the last thing on her mind.
Padron’s aunt died from breast cancer, and she … Read more
The primary end point was not met in the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of tumor treating fields therapy plus paclitaxel in patients with platinum-resistant ovarian cancer.
Patients with platinum-resistant ovarian cancer given tumor treating fields
The prevalence of distress among women with late-stage gynecologic cancers calls for well-designed studies to assess the safety and efficacy of psychedelics for this patient population, according to authors of a published commentary.
Psychedelics — specifically psilocybin — have shown … Read more
DNA can be damaged by toxins, radiation, or even normal cell division, but human cells must continually fix DNA breaks to survive. In cells that cannot repair DNA effectively, changes (mutations) can occur that lead to cancer.
Most cells rely … Read more
The search for preventions and cures has turned inward—focusing on the immune system to stop ovarian cancer.
Professor Paul Hertzog’s research group at Hudson Institute of Medical Research has been working to expand on their discovery of a naturally occurring … Read more
A new drug approval is providing hope for many people living with ovarian cancer.
Some women have what is known as “platinum-resistant” cancer, that means the disease is no longer responding to platinum-based chemotherapy, the most common chemo drug used … Read more
Ovarian cancer is particularly difficult to detect, as the disease often does not produce significant symptoms until it has reached late stages and caused metastasis. New screening methods would help physicians detect ovarian tumors early and dramatically increase the chances … Read more
A new study describes a new diagnostic approach that could help identify the 15% of women with ovarian cancer whose tumors are intrinsically refractory to standard platinum-based therapies, the most common type of chemotherapy for the disease.
Most ovarian cancers … Read more
The addition of batiraxcept to paclitaxel did not significantly improve progression-free survival compared with paclitaxel alone in a prespecified subset of patients with platinum-resistant ovarian cancer who were not previously exposed to bevacizumab, missing the primary end point of the … Read more
